Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology · Chronic Myeloid Leukemia

Tracking Your Progress: Monitoring and PCR Results

At a Glance

CML treatment response is tracked with regular quantitative PCR blood tests that measure BCR::ABL1 on the International Scale. Milestones at 3, 6, and 12 months help doctors assess response, while one higher result does not always mean treatment failure.

Monitoring Chronic Myeloid Leukemia (CML) is different from many other cancers. Instead of relying primarily on scans, your care team uses a highly sensitive blood test called quantitative PCR (qPCR) to track the amount of leukemia-related RNA transcripts (BCR::ABL1) in your blood relative to a control gene [1][2].

This test is so precise it can detect very low levels of leukemia cells [3]. To make these results easy to compare between different hospitals and countries, they are reported on the International Scale (IS), which shows your “leukemia load” as a percentage [4]. Note that this IS percentage is not simply the percentage of leukemia cells in your body, and an “undetectable” result means the amount is below that specific sample’s validated detection limit—not necessarily that the disease is eradicated.

Typically, testing is done about every 3 months early in treatment, and less frequently once a stable response is reached, though your team may individualize this.

The Three Key Milestones

Your doctors look for specific “milestones” at set times to ensure your treatment is working effectively. These targets are based on guidelines from the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN) [5][1].

Timeframe Optimal Target (BCR::ABL1 IS) What It Means
3 Months ≤ 10% Early Molecular Response (EMR): Indicates the medication has successfully begun to shut down the “leukemia engine” [6].
6 Months ≤ 1% A critical stepping stone toward deeper responses and long-term stability [7].
12 Months ≤ 0.1% Major Molecular Response (MMR): Reaching this level is a major achievement, as it significantly reduces the risk of the disease progressing [5][8].

Understanding “Deep” Molecular Response

Once you achieve MMR (0.1%), your team may talk about reaching even lower levels, known as Deep Molecular Response (DMR). These are categorized by how many “logs” (powers of 10) the leukemia has been reduced (provided the assay has sufficient quality and sensitivity to interpret them):

  • MR4 (≤ 0.01% IS): A 4-log reduction [9].
  • MR4.5 (≤ 0.0032% IS): A 4.5-log reduction. At this stage, the leukemia is at extremely low or even “undetectable” levels [10].

Reaching a sustained DMR (usually MR4 or MR4.5 for at least two years) is the primary requirement for patients who wish to discuss Treatment-Free Remission—stopping medication under strict medical supervision [11][12].

Navigating Fluctuations and “Warnings”

It is common for PCR results to bounce slightly up and down. A single result that is slightly higher than the last one does not always mean your treatment is failing.

When a Result is a “Warning” or “Failure”

  • Warning: This means your levels are not dropping as fast as hoped, or a result has “stalled” just above a milestone. Your doctor will likely monitor you more frequently (e.g., every 4 to 8 weeks) rather than changing drugs immediately [5][13].
  • Failure: According to ELN/NCCN guidelines, failure might include a confirmed value of >10% at 3 months, losing a previously reached response, or developing certain resistance mutations. A rise from 0.1% to 1% is evaluated in context and requires confirmation [14][15].

Interpreting a Rising Result

If a single PCR test shows a rise, your doctor will likely investigate three things before switching your medication:

  1. Adherence: Even a few missed doses can cause a temporary rise in PCR levels [16].
  2. Laboratory Consistency: PCR tests can vary between different labs. Using a laboratory calibrated to the International Scale is crucial. It is preferable to use the same laboratory for every test to ensure the “trend” is accurate, but do not delay a test just to stay with one facility [4][17].
  3. Drug Interactions: Certain supplements (like St. John’s Wort) or medications can alter TKI levels. For instance, acid-dependent TKIs like dasatinib interact heavily with proton-pump inhibitors (PPIs) used for acid reflux [P-130]. Ask before stopping or adding any medication.

If a rise is confirmed or there is inadequate response, your doctor may order a mutation analysis to see if your leukemia has developed a resistance to your current drug, helping them choose the best alternative [14][18].

Common questions in this guide

How often are PCR tests done for CML?
PCR testing is commonly done about every three months early in CML treatment. Once the response is stable, testing may be spaced farther apart, but the schedule is individualized by the care team.
What does a quantitative PCR test show in CML?
It measures leukemia-related BCR::ABL1 RNA in a blood sample and reports the result as a percentage on the International Scale. The percentage helps compare results over time, but it is not the literal percentage of leukemia cells in the body.
What CML PCR levels are expected at 3, 6, and 12 months?
The usual optimal targets are 10% or lower at 3 months, 1% or lower at 6 months, and 0.1% or lower at 12 months. The 12-month target is called a major molecular response and is associated with a lower risk of progression. Doctors interpret each result with the full clinical picture.
Does an undetectable CML PCR result mean the leukemia is gone?
No. It means the amount of BCR::ABL1 was below that test sample’s validated detection limit, which can vary with test sensitivity. It does not prove that all leukemia cells have been eliminated, so monitoring and prescribed treatment should continue unless a specialist directs otherwise.
What should I do if my CML PCR result rises?
One higher result does not always mean treatment is failing because small changes can reflect normal laboratory variation. Your doctor may review missed doses, other medicines or supplements, and whether the same standardized laboratory was used, then repeat or confirm the result. If the rise persists, mutation testing may help guide treatment.
When can a person with CML consider stopping treatment?
A sustained very deep molecular response, often called MR4 or MR4.5 for at least two years, is the primary requirement for discussing treatment-free remission. Other eligibility factors apply, and stopping a tyrosine kinase inhibitor should only be considered with a CML specialist and strict, ongoing PCR monitoring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my exact BCR::ABL1 percentage on the International Scale (IS) for my most recent test?
  2. 2.If my result was 'undetectable,' what was the level of sensitivity (the 'limit of detection') for that specific test?
  3. 3.Does the laboratory used for my tests participate in a standardization program to ensure my IS results are accurate?
  4. 4.If we see a slight rise in my numbers, at what point do you consider it a 'confirmed' change rather than normal lab variation?
  5. 5.Do I need a BCR::ABL1 mutation test to see if my current medication is still the best option for me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Deininger MW, Shah NP, Altman JK, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(10)):1385-1415.

    PMID: 33022644
  2. 2

    Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

    Möbius S, Schenk T, Himsel D, et al.

    Journal of cancer research and clinical oncology 2019; (145(6)):1645-1650 doi:10.1007/s00432-019-02910-6.

    PMID: 30941573
  3. 3

    Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

    Hochhaus A, Rosti G, Cross NC, et al.

    Leukemia 2016; (30(1)):57-64 doi:10.1038/leu.2015.270.

    PMID: 26437782
  4. 4

    Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

    White HE, Salmon M, Albano F, et al.

    Leukemia 2022; (36(7)):1834-1842 doi:10.1038/s41375-022-01607-z.

    PMID: 35614319
  5. 5

    A review of the European LeukemiaNet recommendations for the management of CML.

    Baccarani M, Castagnetti F, Gugliotta G, Rosti G

    Annals of hematology 2015; (94 Suppl 2()):S141-7 doi:10.1007/s00277-015-2322-2.

    PMID: 25814080
  6. 6

    Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

    Kizaki M, Takahashi N, Iriyama N, et al.

    International journal of hematology 2019; (109(4)):426-439 doi:10.1007/s12185-019-02613-1.

    PMID: 30762219
  7. 7

    Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.

    Wang R, Cong Y, Li C, et al.

    Medicine 2019; (98(15)):e15222 doi:10.1097/MD.0000000000015222.

    PMID: 30985724
  8. 8

    Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.

    Shanmuganathan N, Wadham C, Shahrin N, et al.

    Haematologica 2023; (108(9)):2380-2395 doi:10.3324/haematol.2022.282184.

    PMID: 36951160
  9. 9

    ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.

    Shojaei M, Rezvani H, Azarkeivan A, Poopak B

    Laboratory medicine 2021; (52(2)):158-167 doi:10.1093/labmed/lmaa052.

    PMID: 32821940
  10. 10

    Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.

    Nee A, Lipton JH, Kim DDH

    Leukemia & lymphoma 2022; (63(1)):162-169 doi:10.1080/10428194.2021.1961234.

    PMID: 34379028
  11. 11

    Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.

    Pavlovsky C, Abello Polo V, Pagnano K, et al.

    Blood advances 2021; (5(23)):4855-4863 doi:10.1182/bloodadvances.2020003235.

    PMID: 34438444
  12. 12

    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

    Ross DM, Masszi T, Gómez Casares MT, et al.

    Journal of cancer research and clinical oncology 2018; (144(5)):945-954 doi:10.1007/s00432-018-2604-x.

    PMID: 29468438
  13. 13

    Molecular monitoring in chronic myeloid leukemia-how low can you go?

    Branford S

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):156-163 doi:10.1182/asheducation-2016.1.156.

    PMID: 27913475
  14. 14

    Resistance mutations in CML and how we approach them.

    Soverini S

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):469-475 doi:10.1182/hematology.2023000447.

    PMID: 38066920
  15. 15

    Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.

    Chandran RK, Geetha N, Sakthivel KM, et al.

    Gene 2019; (686()):85-91 doi:10.1016/j.gene.2018.11.005.

    PMID: 30399426
  16. 16

    Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia.

    Crampe M, Andrews C, Fortune A, Langabeer SE

    Case reports in hematology 2017; (2017()):3548936 doi:10.1155/2017/3548936.

    PMID: 29375916
  17. 17

    Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts.

    Smith BM, Brewer D, Druker BJ, Braun TP

    Case reports in oncology 2021; (14(3)):1707-1711 doi:10.1159/000520400.

    PMID: 35082629
  18. 18

    Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

    Soverini S, Bavaro L, De Benedittis C, et al.

    Blood 2020; (135(8)):534-541 doi:10.1182/blood.2019002969.

    PMID: 31877211

This page explains CML PCR monitoring for informational purposes only and does not constitute medical advice. Your hematologist should interpret your results and guide treatment decisions.

Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.